氨磷汀联合化疗治疗Ewing肉瘤/PNET的临床观察

Efficacy of amifostine combined with chemotherapy for patients with Ewing sarcoma or PNET

目的探讨氨磷汀联合化疗治疗Ewing肉瘤/PNET的疗效、不良反应和安全性。方法 32例Ewing肉瘤/PNET患者分为化疗加氨磷汀组(观察组)及单纯化疗组(对照组),观察组12例,对照组20例。行IFO-IFO-DDP-ADM化疗2周期后评价疗效、不良反应。结果观察组完全缓解(CR)及非常好的部分缓解率(VGPR)为91.6%,对照组为90.0%,两组比较差异无统计学意义(P>0.05)。比较两组各种Ⅰ度～Ⅳ度不良反应发生率,差异无统计学意义(P>0.05)。比较两组发生的Ⅳ度不良反应,观察组Ⅳ度白细胞减少为25.0%,对照组为70.0%;观察组Ⅳ度粒细胞减少25.0%,对照组为75.0%,差异均有统计学意义(P<0.05)。结论氨磷汀联合化疗治疗Ewing肉瘤/PNET不改变化疗疗效,不增加各种常见不良反应发生率;可以明显减少化疗后Ⅳ度白细胞及粒细胞减少的发生率,安全性好。

Objective To investigate the efficacy and adverse reactions of chemotherapy combined with amifostine for patients with Ewing sarcoma or primary neuroectodermal tumor（PNET）.Methods Thirty-two patients with Ewing sarcoma/PNET were divided into Group A（amifostine group,n=12） and Group B（control group,n=20）.After two cycles of IFO-IFO-DDP-ADM chemotherapy,the efficacy and adverse reaction of chemotherapy were observed.Results The rate of complete remission（CR） and very good partial response（VGPR） was 91.6% in Group A,and 90.0% in Group B（P 0.05）.There was no significant difference in rate of adverse reaction Ⅰ~Ⅳ between two groups（P 0.05）.The rate of Ⅳ leukopenia in Group A was 25.0% and 70.0% in Group B（P0.05）.The rate of Ⅳ neutropenia in Group A was 25.0% and 75.0% in Group B（P0.05）.Conclusion Amifostine combined with chemotherapy for patients with Ewing sarcoma/PNET may not change the efficacy or adverse reaction,while the rate of Ⅳ leukopenia and neutropenia would be reduced.